istiratumab   

GtoPdb Ligand ID: 8930

Synonyms: MM-141 | MM141
Compound class: Antibody
Comment: Istiratumab (MM-141) is a fully human bispecific monoclonal antibody co-targeting the IGF-I receptor (IGF-IR) and epidermal growth factor receptor ERBB3 that was developed by Merrimack Pharmaceuticals to block tumour survival signals [1,3,5].
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record.
Bioactivity Comments
The potency of bispecific MM-141 is superior to that using either monospecific or combination antibody therapies targeting the same receptors [3].
Selectivity at catalytic receptors
Key to terms and symbols Click column headers to sort
Target Sp. Type Action Value Parameter Concentration range (M) Reference
erb-b2 receptor tyrosine kinase 3 Hs Antibody Binding >9.0 pKd - 3
pKd >9.0 (Kd <1x10-9 M) [3]
Insulin-like growth factor I receptor Hs Antibody Binding >9.0 pKd - 3
pKd >9.0 (Kd <1x10-9 M) [3]